Skip to main content
Premium Trial:

Request an Annual Quote

IBM Plans to Increase Life Science Investment in 2001

NEW YORK, Dec 18 – An IBM spokeswoman said Monday that the company intends to augment the $100 million life sciences initiative it launched in August to develop IT solutions for biotechnology, genomic, e-health, pharmaceutical, agri-science, and other life sciences industries.

While the full amount has not yet been determined, IBM spokeswoman Theo Chisholm told GenomeWeb that the company may increase the initial investment up to $100 million over the course of the year.

The funds would be directed toward “forming new partnerships and increasing the sales force in the United States and Europe,” according to Chisholm.

The additional investment “reflects our confidence in the growth of this sector,” Chisholm said.

Since August IBM has invested in technology partnerships with Incyte Genomics, First Genetic Trust, and Structural Bioinformatics.      

Earlier on Monday, the company announced that it would build a 7.5-teraflop computing cluster for NuTec Sciences of Atlanta.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.